In a surprising turn of events, pharmaceutical manufacturers in Canada have declared they are not collaborating with Florida on the proposed initiative to import Canadian medications. This announcement comes despite the Florida government’s firm stance that this plan is actively progressing.
Since 2019, Florida’s Governor Ron DeSantis has been advocating for a solution to the soaring prices of prescription drugs by suggesting that the state could import these medications from Canada, where they are significantly less expensive. To put this into perspective, data indicates that the average prices for medications in the United States are over three times higher than those found in Canada for identical products.
Currently, Canadian drug manufacturers export approximately $7 billion worth of pharmaceuticals to the United States every year. If they were to sell some products at Canadian prices, it would mean undercutting their existing prices in the U.S., which poses a dilemma for these companies.
In 2024, the U.S. Food and Drug Administration (FDA) granted approval for Florida's drug importation program, but only for a limited duration of two years. However, recent reports from Politico indicate that no medications have yet been shipped under this program, even after Florida invested more than $80 million in establishing a warehouse. Interestingly, this facility is now being used to store emergency supplies for hurricane season instead.
Molly Best, the press secretary for Governor DeSantis, communicated via email to The Globe and Mail that Florida is still pursuing the drug-importation strategy. She stated, "Florida’s vendor has been working diligently to negotiate with Canadian manufacturers and distribution partners to purchase and import eligible prescription drugs into the U.S." Furthermore, she mentioned that meetings with the FDA are scheduled for March, where the state will address the challenges faced by states concerning manufacturers, adding that the FDA's approval has been extended until May 6.
However, organizations representing Canadian drug manufacturers and distributors have stepped forward to clarify that they are not engaged in discussions with Florida regarding this program. Erin Polka, who serves as the vice-president of communications for Innovative Medicines Canada, emphasized that they have not had any conversations with Florida, nor are they aware of any outreach from their member companies.
Similarly, Angelique Berg, the CEO of the Canadian Association for Pharmacy Distribution Management, echoed this sentiment, stating that none of their distributors are currently in talks with Florida. She explained that the lower prices in Canada are a result of the nation's public healthcare system and the unique regulatory mechanisms that control costs. Hence, altering the shipping pathways for these products would not solve the underlying issue of high prices in the U.S. "Quite frankly, the entire idea is bewildering," she remarked.
Following the FDA’s approval of Florida’s plan, Health Canada alerted drug companies, wholesalers, and distributors to refrain from exporting pharmaceuticals in a manner that could exacerbate domestic shortages. This message was reiterated when The Globe reached out for commentary.
Furthermore, Florida's initiative appears to clash with other pharmaceutical pricing strategies introduced during the Trump administration. President Donald Trump had consistently threatened tariffs on pharmaceuticals throughout 2025, including initiating a national security investigation into the drug supply chain and declaring plans to impose 100% tariffs on brand-name drugs produced by companies lacking a manufacturing presence in the United States. These threats, however, did not materialize, and if they had, they might have resulted in higher costs for patients as manufacturers could pass these expenses onto consumers.
In recent developments, the Trump administration has shifted its focus toward negotiating "most favored nation" agreements with drug manufacturers that would aim to reduce U.S. medication prices in exchange for improved reimbursement rates through Medicare.
But here's where it gets controversial: Can Florida's ambitious plan to import drugs from Canada realistically address the broader issues of pharmaceutical pricing in the U.S.? Is it merely a temporary fix in an overly complex healthcare landscape? We invite you to share your thoughts and insights in the comments below!
